The FDA has classified Vitruvias Therapeutics’ recall of thyroid tablets as Class I due to potential superpotency, posing a risk of serious health issues. The affected lot includes approximately 3,655 units.
More in Finance
‘Fixed match’: CJP's Dipke urges opposition to stop contesting ‘rigged' elections amid CEC row
September 25, 2026
Sonam Wangchuk seeks Amit Shah's resignation over Leh violence, fears might be killed in 'encounter' – What we know
September 25, 2026
Pakistan striking Afghanistan to escape Makkah defence pact? Taliban makes big claim — what’s behind it
September 25, 2026
Make in India turns 12: PM Modi highlights growth in manufacturing, investment and exports
September 25, 2026
Tukaram Mundhe effect? Reputation at stake, food businesses become ‘more vigilant’, shift to monthly audits, says report
September 25, 2026
‘Logistical factors’: ECI postpones CEC Gyanesh Kumar’s 2 outreach events in UP amid dissent row
September 25, 2026
Latest News
‘Fixed match’: CJP's Dipke urges opposition to stop contesting ‘rigged' elections amid CEC row
September 25, 2026
Sonam Wangchuk seeks Amit Shah's resignation over Leh violence, fears might be killed in 'encounter' – What we know
September 25, 2026
Pakistan striking Afghanistan to escape Makkah defence pact? Taliban makes big claim — what’s behind it
September 25, 2026
Make in India turns 12: PM Modi highlights growth in manufacturing, investment and exports
September 25, 2026
Tukaram Mundhe effect? Reputation at stake, food businesses become ‘more vigilant’, shift to monthly audits, says report
September 25, 2026
‘Logistical factors’: ECI postpones CEC Gyanesh Kumar’s 2 outreach events in UP amid dissent row
September 25, 2026